Development of diagnostic methods for human diseases, principally for those of the Central Nervous System as the Alzheimer’s disease
Development of diagnostic methods for human diseases, principally for those of the Central Nervous System as the Alzheimer’s disease
During the last years the early initiation of treatments strategy involving clinical assays against the Alzheimer’s disease is becoming popular among the big pharmas, so that there is still an unmet need of tools for the prediction of the disease evolution.
AlzTEST® is a diagnostic tool based on peripheral biomarkers that allow identifying individuals with mild cognitive impairment that have major risk to develop AD. It is the product at the most advanced development phase and it has advantages compared to current diagnostic methods.
Addressed to the early stage of the Alzheimer’s disease
Uses a diagnostic method based on mild cognitive impairment that is considered the early stage of the Alzheimer’s disease and for which currently no accurate diagnosis method is available.
Minimally invasive
The technique used for the sample collection is minimally invasive, a distinguishing factor with current methods on biomarker analysis in biological fluids that requires a lumbar punction to gather cerebrospinal fluid. This difference helps to diminish risk in patients and to diminish extraction costs.
Combination of biomarkers
The use of a biomarker combination from different mechanisms of action involved in the disease will maximize the diagnosis tool, thus providing more specificity and sensitivity.
Neuron Bio has developed a diagnostic method for individuals affected by Smith-Lemli-Opitz syndrome (SLOS) that determines levels of various blood markers related to the disease.